Related references
Note: Only part of the references are listed.Evaluating the Cost-Effectiveness of Early Compared with Late or No Biologic Treatment to Manage Crohn's Disease using Real-World Data
Nadia Pillai et al.
JOURNAL OF CROHNS & COLITIS (2020)
Big data in IBD: big progress for clinical practice
Nasim Sadat Seyed Tabib et al.
GUT (2020)
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
Christian Maaser et al.
JOURNAL OF CROHNS & COLITIS (2019)
Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease
Abhinav Vasudevan et al.
INFLAMMATORY BOWEL DISEASES (2019)
Challenges in IBD Research: Precision Medicine
Lee A. Denson et al.
INFLAMMATORY BOWEL DISEASES (2019)
The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease
Laura E. Targownik et al.
INFLAMMATORY BOWEL DISEASES (2019)
The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
Joyce W. Y. Mak et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Development of an index to define overall disease severity in IBD
Corey A. Siegel et al.
GUT (2018)
Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's disease
Katsuyoshi Matsuoka et al.
PLOS ONE (2018)
Cost-utility Analysis: Thiopurines Plus Endoscopy-guided Biological Step-up Therapy is the Optimal Management of Postoperative Crohn's Disease
Roberto Candia et al.
INFLAMMATORY BOWEL DISEASES (2017)
Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines
Akbar K. Waljee et al.
JOURNAL OF CROHNS & COLITIS (2017)
Time to clinical response and remission for therapeutics in inflammatory bowel diseases: what should the clinician expect, what should patients be told?
Abhinav Vasudevan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm
N. S. Ding et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors
M. G. Ward et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease
Grant E. Barber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study
Tomas Ripolles et al.
INFLAMMATORY BOWEL DISEASES (2016)
Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2016)
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up
Mirthe E. van der Valk et al.
PLOS ONE (2016)
Development and evaluation of multi-marker risk scores for clinical prognosis
Benjamin French et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
Karel G. M. Moons et al.
ANNALS OF INTERNAL MEDICINE (2015)
Usefulness of C-Reactive Protein as a Disease Activity Marker in Crohn's Disease according to the Location of Disease
Dong-Hoon Yang et al.
GUT AND LIVER (2015)
Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012
Petra A. Golovics et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe - An ECCO-EpiCom study
J. Burisch et al.
JOURNAL OF CROHNS & COLITIS (2014)
Predictors for developing intestinal failure in patients with Crohn's disease
Richard B. Gearry et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience
Michael B. Sprakes et al.
JOURNAL OF CROHNS & COLITIS (2012)
Thiopurine treatment in inflammatory bowel disease: Response predictors, safety, and withdrawal in follow-up
Giuseppe Costantino et al.
JOURNAL OF CROHNS & COLITIS (2012)
Incidence, Disease Phenotype at Diagnosis, and Early Disease Course in Inflammatory Bowel Diseases in Western Hungary, 2002-2006
Laszlo Lakatos et al.
INFLAMMATORY BOWEL DISEASES (2011)
Multiple imputation by chained equations: what is it and how does it work?
Melissa J. Azur et al.
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH (2011)
Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort
Kelvin T. Thia et al.
GASTROENTEROLOGY (2010)
Influence of Phenotype at Diagnosis and of Other Potential Prognostic Factors on the Course of Inflammatory Bowel Disease
M. J. L. Romberg-Camps et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Corey A. Siegel et al.
Therapeutic Advances in Gastroenterology (2009)
Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease
Jennifer Jones et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Predictors of severe Crohn's disease
Catherine Loly et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2008)
Clinical course in Crohn's disease: Results of a Norwegian population-based ten-year follow-up study
Inger Camilla Solberg et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
Predictors of Crohn's disease
L Beaugerie et al.
GASTROENTEROLOGY (2006)
Clinically active Crohn's disease in the presence of a low C-reactive protein
THJ Florin et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease
BA Goldenberg et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2004)
Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease
JP Achkar et al.
INFLAMMATORY BOWEL DISEASES (2004)
Review article: maintenance treatment of Crohn's disease
L Biancone et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Inflammatory bowel disease
DK Podolsky
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
AG Fraser et al.
GUT (2002)
6-mercaptopurine metabolite levels in children with inflammatory bowel disease
P Gupta et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2001)
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease
C Cuffari et al.
GUT (2001)
Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease
J Belaiche et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2001)
Time-dependent ROC curves for censored survival data and a diagnostic marker
PJ Heagerty et al.
BIOMETRICS (2000)
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease
MC Dubinsky et al.
GASTROENTEROLOGY (2000)
Share Paper
